Group revenues rose by 20.4% - 23.5% at constant currencies - to Â£252.2m and underlying earnings per share rose by 23.7% to 18.03p.
The group said underlying pre-tax profits rose to Â£21.0m - 46.9% up on a reported basis and 54.2% higher at constant currencies.
The group said its resutls had been driven by solid revenue growth and prudent cost control across all its trading segments and also from the continuing successful integration of Eurovet Animal Health, acquired in May 2012.
It adds: "Our key strategic segments, European Pharmaceuticals and US Pharmaceuticals, have shown good revenue growth from our own licensed branded veterinary products and specialist pet diets.
"Contract manufacturing has seen double digit revenue growth and our Services segment has seen robust revenue growth and a modest improvement in operating margin over the corresponding period last year."
At 8:08am: [LON:DPH] Dechra Pharmaceuticals share price was -7p at 685p
Story provided by StockMarketWire.com